Press release
Leptomeningeal Metastases Pipeline Analysis, Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Treatment Market, Therapies, MOA, ROA, Companies by DelveInsight
Leptomeningeal Metastases Pipeline
"Leptomeningeal Metastases Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Leptomeningeal Metastases Market.
The Leptomeningeal Metastases Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report here @ Leptomeningeal Metastases Pipeline Outlook - https://www.delveinsight.com/report-store/leptomeningeal-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Leptomeningeal Metastases Pipeline Report:
• Leptomeningeal Metastases Companies across the globe are diligently working toward developing novel Leptomeningeal Metastases treatment therapies with a considerable amount of success over the years.
• Leptomeningeal Metastases companies working in the treatment market are Plus Therapeutics, AstraZeneca, Angiochem, Y-mAbs Therapeutics, TYK Medicines, Inc, Seagen Inc., Pfizer, Genentech, Inc., Angiochem Inc, Daiichi Sankyo, Inc., and others, are developing therapies for the Leptomeningeal Metastases treatment
• Emerging Leptomeningeal Metastases therapies such as Rhenium-186 NanoLiposome (186RNL), AZD1390, Paclitaxel trevatide (ANG1005), Omburtamab, and others are expected to have a significant impact on the Leptomeningeal Metastases market in the coming years.
• On January 2024, Plus Therapeutics announced results of a Multicenter Phase 1 Clinical Study to Determine the Maximum Tolerated Dose/Maximum Feasible Dose, Safety, & Efficacy of Single Dose Rhenium-186 NanoLiposome (186RNL) Administered via Intraventricular Catheter for Leptomeningeal Metastases.
• On April 2023, Angiochem announced results of a Randomized Open-Label, Multi-Center Pivotal Study of ANG1005 Compared with Physician's Best Choice in HER2-Negative Breast Cancer Patients with Newly Diagnosed Leptomeningeal Carcinomatosis and Previously Treated Brain Metastases (ANGLeD).
• On March 2022, Kadmon Corporation announced results of A Phase 2, Multicenter Study of Tesevatinib in Subjects with Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases.
Leptomeningeal Metastases Overview
Leptomeningeal metastases (LM), also known as leptomeningeal carcinomatosis, is a severe and advanced complication of cancer where malignant cells spread to the leptomeninges, the two innermost layers of tissue covering the brain and spinal cord. This condition occurs in 5-8% of all cancer patients, with higher incidences in those with cancers of the breast, lung, and melanoma.
Leptomeningeal metastases occurs when cancer cells migrate through the bloodstream or directly invade the cerebrospinal fluid (CSF). These cells can then disseminate throughout the central nervous system (CNS), leading to widespread neurological symptoms. Common Leptomeningeal metastases symptoms include headache, nausea, vomiting, changes in mental status, cranial nerve deficits, back pain, and motor or sensory disturbances.
Diagnosis of Leptomeningeal metastases typically involves imaging studies like MRI, which can reveal abnormalities in the meninges, and lumbar puncture to analyze CSF for malignant cells or elevated protein levels
Treatment options for Leptomeningeal metastases are limited and primarily palliative, focusing on alleviating symptoms and improving quality of life. They include intrathecal chemotherapy (delivered directly into the CSF), systemic chemotherapy, radiation therapy, and corticosteroids to reduce inflammation and pressure. Despite treatment, the prognosis for Leptomeningeal metastases remains poor, with a median survival time of a few months. Early detection and intervention are crucial for managing symptoms and prolonging survival.
Get a Free Sample PDF Report to know more about Leptomeningeal Metastases Pipeline Therapeutic Assessment- Leptomeningeal Metastases Treatment Market - https://www.delveinsight.com/sample-request/leptomeningeal-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Leptomeningeal Metastases Route of Administration
Leptomeningeal Metastases pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Leptomeningeal Metastases Molecule Type
Leptomeningeal Metastases Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Leptomeningeal Metastases Pipeline Therapeutics Assessment
• Leptomeningeal Metastases Assessment by Product Type
• Leptomeningeal Metastases By Stage and Product Type
• Leptomeningeal Metastases Assessment by Route of Administration
• Leptomeningeal Metastases By Stage and Route of Administration
• Leptomeningeal Metastases Assessment by Molecule Type
• Leptomeningeal Metastases by Stage and Molecule Type
DelveInsight's Leptomeningeal Metastases Report covers around 5+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Leptomeningeal Metastases product details are provided in the report. Download the Leptomeningeal Metastases pipeline report to learn more about the emerging Leptomeningeal Metastases therapies- Leptomeningeal Metastases Therapeutic Assessment - https://www.delveinsight.com/report-store/leptomeningeal-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Leptomeningeal Metastases Pipeline Analysis:
The Leptomeningeal Metastases pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Leptomeningeal Metastases with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Leptomeningeal Metastases Treatment.
• Leptomeningeal Metastases key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Leptomeningeal Metastases Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Leptomeningeal Metastases market.
Download Sample PDF Report to know more about Leptomeningeal Metastases drugs and therapies- Leptomeningeal Metastases Clinical Trials and FDA Approvals - https://www.delveinsight.com/sample-request/leptomeningeal-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of Leptomeningeal Metastases Pipeline Drug Insight
• Coverage: Global
• Key Leptomeningeal Metastases Companies: Plus Therapeutics, AstraZeneca, Angiochem, Y-mAbs Therapeutics, TYK Medicines, Inc, Seagen Inc., Pfizer, Genentech, Inc., Angiochem Inc, Daiichi Sankyo, Inc., and others.
• Key Leptomeningeal Metastases Therapies: Rhenium-186 NanoLiposome (186RNL), AZD1390, Paclitaxel trevatide (ANG1005), Omburtamab, and others.
• Leptomeningeal Metastases Therapeutic Assessment: Leptomeningeal Metastases current marketed and Leptomeningeal Metastases emerging therapies
• Leptomeningeal Metastases Market Dynamics: Leptomeningeal Metastases market drivers and Leptomeningeal Metastases market barriers
Request for Sample PDF Report for Leptomeningeal Metastases Pipeline Assessment and clinical trials - Leptomeningeal Metastases Drugs and Therapies - https://www.delveinsight.com/sample-request/leptomeningeal-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Leptomeningeal Metastases Report Introduction
2. Leptomeningeal Metastases Executive Summary
3. Leptomeningeal Metastases Overview
4. Leptomeningeal Metastases- Analytical Perspective In-depth Commercial Assessment
5. Leptomeningeal Metastases Pipeline Therapeutics
6. Leptomeningeal Metastases Late Stage Products (Phase II/III)
7. Leptomeningeal Metastases Mid Stage Products (Phase II)
8. Leptomeningeal Metastases Early Stage Products (Phase I)
9. Leptomeningeal Metastases Preclinical Stage Products
10. Leptomeningeal Metastases Therapeutics Assessment
11. Leptomeningeal Metastases Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Leptomeningeal Metastases Companies
14. Leptomeningeal Metastases Key Products
15. Leptomeningeal Metastases Unmet Needs
16 . Leptomeningeal Metastases Market Drivers and Barriers
17. Leptomeningeal Metastases Future Perspectives and Conclusion
18. Leptomeningeal Metastases Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports:
• Adrenal Cortex Neoplasms Market: https://www.delveinsight.com/report-store/adrenocortical-carcinoma-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Neuroblastoma Market: https://www.delveinsight.com/report-store/neuroblastoma-market
• Pharma Licensing Services: https://www.delveinsight.com/consulting/licensing-services
• Allergic Rhinitis Market: https://www.delveinsight.com/report-store/allergic-rhinitis-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Burkitt Lymphoma Market: https://www.delveinsight.com/report-store/burkitt-lymphoma-market
• Chronic Rhinosinusitis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-market
• Chronic Rhinosinustis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-market
• Contraceptive Devices Market: https://www.delveinsight.com/report-store/contraceptive-devices-market
• Febrile Neutropenia Market: https://www.delveinsight.com/report-store/febrile-neutropenia-market
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Non-st Segment Elevation Acute Coronary Syndromes Market: https://www.delveinsight.com/report-store/non-st-segment-elevation-acute-coronary-syndromes-nste-acss-market
• Nsclc Market: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Walking Impairment In Multiple Sclerosis Market: https://www.delveinsight.com/report-store/walking-impairment-in-multiple-sclerosis-market
• Acute On Liver Failure Market: https://www.delveinsight.com/report-store/acute-liver-failure-market
• Alopecia Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Anal Cancer Market: https://www.delveinsight.com/report-store/anal-cancer-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Arteriovenous Fistula Market: https://www.delveinsight.com/report-store/arteriovenous-fistula-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/
Case Study: https://www.delveinsight.com/case-study/conference-intelligence-product-assessment
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Leptomeningeal Metastases Pipeline Analysis, Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Treatment Market, Therapies, MOA, ROA, Companies by DelveInsight here
News-ID: 3815056 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Leptomeningeal
Leptomeningeal Metastases Market Size, Share and Growth Report, 2034
Introduction
The Leptomeningeal Metastases (LM) market is gaining increased attention as survival rates for primary cancers improve, leading to higher detection of late-stage complications like LM. This rare but severe condition occurs when cancer cells spread to the leptomeninges and cerebrospinal fluid (CSF), most often from breast cancer, lung cancer, or melanoma. Historically associated with poor prognosis, LM treatment is evolving with advancements in molecular diagnostics, targeted therapies, intrathecal drug delivery…
Trailhead Biosystems® Develops iPSC-Derived Vascular Leptomeningeal Cells
Beachwood, Ohio, March 5, 2025 - Trailhead Biosystems, Inc. (trailbio.com), a biotechnology company pioneering the creation of iPSC-derived human cells at scale for drug discovery and cell therapy, proudly announces the launch of TrailBio® Vascular Leptomeningeal Cells. As the first of their kind on the market, these unique cells provide researchers with a new tool to directly study the blood-brain barrier's permeability and regulatory mechanisms. This advancement represents a significant…
Leptomeningeal Metastases Market Anticipated to Expand Rapidly During 2024-2034, …
The Leptomeningeal Metastases market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Leptomeningeal Metastases pipeline products will significantly revolutionize the Leptomeningeal Metastases market dynamics.
DelveInsight's "Leptomeningeal Metastases Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Leptomeningeal Metastases, historical and forecasted epidemiology as well as the Leptomeningeal Metastases market trends in the United…
Leptomeningeal Metastases Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical …
Leptomeningeal Metastases companies are Plus Therapeutics, AstraZeneca, Angiochem, Y-mAbs Therapeutics, TYK Medicines, Inc, Seagen Inc., Pfizer, Genentech, Inc., Angiochem Inc, Daiichi Sankyo, and others.
(Albany, USA) DelveInsight's "Leptomeningeal Metastases Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Leptomeningeal Metastases, historical and forecasted epidemiology as well as the Leptomeningeal Metastases market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Leptomeningeal Metastases…
Leptomeningeal Metastases Treatment Market 2034: EMA, PDMA, FDA Approvals, Clini …
Leptomeningeal Metastases companies working in the market are Plus Therapeutics, AstraZeneca, Angiochem, Y-mAbs Therapeutics, TYK Medicines, Inc, Seagen Inc., Pfizer, Genentech, Inc., Angiochem Inc, Daiichi Sankyo, Inc., and others.
(Albany, USA) DelveInsight's "Leptomeningeal Metastases Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Leptomeningeal Metastases, historical and forecasted epidemiology as well as the Leptomeningeal Metastases market trends in the United States, EU5 (Germany, Spain, Italy, France, and United…
Leptomeningeal Metastases Treatment Market Size, Forecast, Drugs, and Companies …
Leptomeningeal Metastases Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Leptomeningeal Metastases Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Leptomeningeal Metastases Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Leptomeningeal Metastases, historical and…
